Background The effects of omega-3 fatty acids (FAs), such as eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids, on cardiovascular outcomes are uncertain. We aimed to …

Patients with well-controlled LDL (low-density lipoprotein) levels still have residual
cardiovascular risk associated with elevated triglycerides. Epidemiological studies have …

Background Patients with elevated triglyceride levels are at increased risk for ischemic
events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers …

Aims Despite the effects of statins in reducing cardiovascular events and slowing
progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains …

Over the last 3 decades there have been substantial improvements in treatments aimed at
reducing cardiovascular (CV) events. As these treatments have been developed, there have …

Background: In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of
ischemic events, including cardiovascular death, among patients with elevated triglycerides …

Abstract Purpose of Review The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …

Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide
and has been characterized as a chronic immunoinflammatory, fibroproliferative disease …

Abstract Purpose of Review Treatment of hypercholesterolemia with statins results in
significant reductions in cardiovascular risk; however, individuals with well-controlled low …

Eicosapentaenoic acid (EPA) is a key anti-inflammatory/anti-aggregatory long-chain
polyunsaturated omega-3 fatty acid. Conversely, the omega-6 fatty acid, arachidonic acid …